FDA Grants Breakthrough Status to AI Breast Cancer Risk Tool
A new AI-powered software analyzes mammograms to predict a woman's personalized five-year risk of developing breast cancer, earning the FDA’s Breakthrough Device designation.
Mammo
Dive into developments in breast imaging, including digital breast tomosynthesis, contrast-enhanced mammography, and AI-driven lesion detection. Regular updates include clinical studies, regulatory news, and technological innovations designed to improve early detection and workflow efficiency.
